| Identification | Back Directory | [Name]
Palmitoleoyl 3-carbacyclic Phosphatidic Acid | [CAS]
910228-13-6 | [Synonyms]
IAGUMCXYAAGWJD-FPLPWBNLSA-N
Palmitoleoyl 3-carbacyclic Phosphatidic Acid
Palmitoleoyl 3-carbacyclic Phosphatidic Acid Exclusive
9-Hexadecenoic acid, (2-hydroxy-2-oxido-1,2-oxaphospholan-5-yl)methyl ester, (9Z)- | [Molecular Formula]
C20H37O5P | [MDL Number]
MFCD18427963 | [MOL File]
910228-13-6.mol | [Molecular Weight]
388.48 |
| Hazard Information | Back Directory | [Description]
Cyclic phosphatidic acids (cPAs) are naturally occurring analogs of lysophosphatidic acid (LPA) in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate.1,2 Carba-derivatives of cPA (ccPA) are modified at the sn-2 (2-ccPA) or sn-3 (3-ccPA) linkage, preventing the opening of cPA to produce lysophosphatidic acid (LPA).3 Palmitoleoyl 3-carbacyclic phosphatidic acid (3-ccPA 16:1) is a cyclic LPA analog that contains the 16:1 fatty acid, palmitoleate, at the sn-1 position of the glycerol backbone.3 At 25 μM, it inhibits the transcellular migration of MM1 cells across mesothelial cell monolayers in response to fetal bovine serum (86.9%) or LPA (99.9%) without affecting proliferation.3 3-ccPA 16:1 significantly inhibits autotaxin (IC50 = 620 nM),4 an enzyme that is important in cancer cell survival, growth, migration, invasion and metastasis. When delivered intraperitoneally, 3-ccPA 16:1 significantly reduces the number of lung metastases formed in mice injected with B16F10 melanoma cells in the tail vein.4 | [Uses]
Palmitoleoyl 3-carbacyclic phosphatidic acid (3ccPA 16:1) is an intermediately potent inhibitor of autotaxin (ATX) with an IC50 of 620 nM. Palmitoleoyl 3-carbacyclic phosphatidic acid can be used for melanoma research[1]. | [in vivo]
Palmitoleoyl 3-carbacyclic phosphatidic acid (250 μg/kg, i.p., 15 min and 48 h after the i.v. of 5 × 105 B16F10 melanoma cells per mouse) blocks 1/3 of the lung metastasis of melanoma cells (37±10 tumors) compared with vehicle control (57±14 tumors)[1].
| [References]
1. Kobayashi, T., Tanaka-Ishii, R., Taguchi, R., et al. Existence of a bioactive lipid, cyclic phosphatidic acid, bound to human serum albumin Life Sci. 65(21),2185-2191(1999).
2. Mukai, M., Imamura, F., Ayaki, M., et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA) Int. J. Cancer 81,918-922(1999).
3. Uchiyama, A., Mukai, M., Fujiwara, Y., et al. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid Biochim. Biophys. Acta 1771,103-112(2007).
4. Baker, D.L., Fujiwara, Y., Pigg, K.R., et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis J. Biol. Chem. 281(32),22786-22793(2006). |
|
|